Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaprevir + Peginterferon alfa + Ribavirin in HIV/HCV Genotype 1 Coinfected Patients with Severe Fibrosis or Compensated Cirrhosis
2011-003593-85Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of telaprevir in Hepatitis C genotype 1 and human immunodeficiency virus infection (HIV), sponsored by Janssen Pharmaceutical. Primary endpoint: Treatment-emergent adverse events. Started Dec 2011; status: completed.
02
Drugs
telaprevir
03
Conditions
Hepatitis C genotype 1human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2011-003593-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003593-85.